Association between EGF promoter polymorphisms and cancer risk: a meta-analysis

[1]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[2]  D. Christiani,et al.  Epidermal growth factor A61G gene polymorphism, gastroesophageal reflux disease and esophageal adenocarcinoma risk. , 2009, Carcinogenesis.

[3]  P. Ascierto,et al.  Role of the EGF +61A>G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls , 2009, BMC dermatology.

[4]  Xiangmei Chen,et al.  No association between EGF +61 A/G polymorphism and increased risk of glioma. , 2009, The International journal of biological markers.

[5]  R. Medeiros,et al.  Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility , 2009, The Pharmacogenomics Journal.

[6]  Daniela Pinto,et al.  Epidermal growth factor genetic variation, breast cancer risk, and waiting time to onset of disease. , 2009, DNA and cell biology.

[7]  K. Czene,et al.  Common genetic variability in ESR1 and EGF in relation to endometrial cancer risk and survival , 2009, British Journal of Cancer.

[8]  R. Catarino,et al.  Ovarian Cancer and Genetic Susceptibility: Association of A61G Polymorphism in the EGF Gene , 2009, Experimental biology and medicine.

[9]  G. Muslimov.  Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma , 2008, Bulletin of Experimental Biology and Medicine.

[10]  Weibo Liang,et al.  No association between epidermal growth factor and epidermal growth factor receptor polymorphisms and nasopharyngeal carcinoma. , 2008, Cancer genetics and cytogenetics.

[11]  Hongbing Shen,et al.  EGF promoter SNPs, plasma EGF levels and risk of breast cancer in Chinese women , 2008, Breast Cancer Research and Treatment.

[12]  B. Mittal,et al.  Genetic susceptibility of epidermal growth factor +61A>G and transforming growth factor beta1 -509C>T gene polymorphisms with gallbladder cancer. , 2008, Human immunology.

[13]  D. Pinto,et al.  Genetic Polymorphism in EGF Is Associated with Prostate Cancer Aggressiveness and Progression-Free Interval in Androgen Blockade–Treated Patients , 2008, Clinical Cancer Research.

[14]  N. Nishioka,et al.  A Functional Epidermal Growth Factor (EGF) Polymorphism, EGF Serum Levels, and Esophageal Adenocarcinoma Risk and Outcome , 2008, Clinical Cancer Research.

[15]  M. Thun,et al.  Polymorphisms in Angiogenesis-Related Genes and Prostate Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[16]  A. Sjölander,et al.  ESR1 and EGF genetic variation in relation to breast cancer risk and survival , 2008, Breast Cancer Research.

[17]  T. Fujii,et al.  Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. , 2008, JAMA.

[18]  C. H. Kim,et al.  +61A>G polymorphism in the EGF gene does not increase the risk of lung cancer , 2007, Respirology (Carlton South. Print).

[19]  U. Ghoshal,et al.  Influence of apoptosis (BCL2, FAS), Cell cycle (CCND1) and growth factor (EGF, EGFR) genetic polymorphisms on survival outcome: An exploratory study in squamous cell esophageal cancer , 2007, Cancer biology & therapy.

[20]  Hans Skovgaard Poulsen,et al.  Mechanisms for oncogenic activation of the epidermal growth factor receptor. , 2007, Cellular signalling.

[21]  Hongbing Shen,et al.  Variant genotypes and haplotypes of the epidermal growth factor gene promoter are associated with a decreased risk of gastric cancer in a high‐risk Chinese population , 2007, Cancer science.

[22]  R. Reis,et al.  Association between Functional EGF+61 Polymorphism and Glioma Risk , 2007, Clinical Cancer Research.

[23]  I. Brandslund,et al.  Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer , 2007, Acta oncologica.

[24]  E. Henson,et al.  Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. , 2006, Cellular signalling.

[25]  H. Pehamberger,et al.  The EGF A61G polymorphism is associated with disease-free period and survival in malignant melanoma. , 2006, The Journal of investigative dermatology.

[26]  J. W. Kim,et al.  Epidermal growth factor 61 A/G polymorphism and uterine cervical cancer , 2006, International Journal of Gynecologic Cancer.

[27]  Y. Goto,et al.  No Association Between EGF Gene Polymorphism and Gastric Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[28]  Kazuhiro Yoshida,et al.  A Single Nucleotide Polymorphism in the 5′ Untranslated Region of the EGF Gene Is Associated with Occurrence and Malignant Progression of Gastric Cancer , 2005, Pathobiology.

[29]  Yeon-Hee Park,et al.  Epidermal growth factor gene polymorphism is different between schizophrenia and lung cancer patients in Korean population , 2005, Neuroscience Letters.

[30]  D. Duffy,et al.  Epidermal growth factor gene (EGF) polymorphism and risk of melanocytic neoplasia. , 2004, The Journal of investigative dermatology.

[31]  J. Barrett,et al.  The relationship between the epidermal growth factor (EGF) 5'UTR variant A61G and melanoma/nevus susceptibility. , 2004, The Journal of investigative dermatology.

[32]  Jennifer L. Schwartz,et al.  EGF gene polymorphism and the risk of incident primary melanoma. , 2004, Cancer research.

[33]  R. Weil,et al.  A Functional Polymorphism in the EGF Gene Is Found with Increased Frequency in Glioblastoma Multiforme Patients and Is Associated with More Aggressive Disease , 2004, Cancer Research.

[34]  A. Bateman,et al.  EGF +61 gene polymorphism and susceptibility to and prognostic markers in cutaneous malignant melanoma , 2003, International journal of cancer.

[35]  Manuel Hidalgo,et al.  Developing inhibitors of the epidermal growth factor receptor for cancer treatment. , 2003, Journal of the National Cancer Institute.

[36]  N. Normanno,et al.  Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. , 2003, Endocrine-related cancer.

[37]  Andrew G Smith,et al.  Association between functional polymorphism in EGF gene and malignant melanoma , 2002, The Lancet.

[38]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[39]  S. Fenton,et al.  Characterization of the Mouse Epidermal Growth Factor Promoter and 5′-Flanking Region , 1996, The Journal of Biological Chemistry.

[40]  L. Sheffield,et al.  Prolactin Inhibits Epidermal Growth Factor-induced Ras-MAPK Signaling in Mammary Epithelial Cells* , 1996, The Journal of Biological Chemistry.

[41]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[42]  J. Megyesi,et al.  Regulation of transcription by the rat EGF gene promoter in normal and ischemic murine kidney cells. , 1995, The American journal of physiology.

[43]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[44]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[45]  W. G. Cochran.  The combination of estimates from different experiments. , 1954 .

[46]  Jia Wang,et al.  Association Between Epidermal Growth Factor Polymorphism and Esophageal Squamous Cell Carcinoma Susceptibility , 2008, Digestive Diseases and Sciences.

[47]  M. Keese,et al.  Association Between EGF, TGF-β1, VEGF Gene Polymorphism and Colorectal Cancer , 2008, World Journal of Surgery.

[48]  U. Ghoshal,et al.  Interaction of EGFR 497Arg>Lys with EGF +61A>G polymorphism: modulation of risk in esophageal cancer. , 2008, Oncology research.

[49]  Gao Chun-fang.  Relationship between Polymorphism of Epidermal Growth Factor 5'UTR Variant G61A Gene and Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection in China , 2008 .

[50]  M. Sanson,et al.  The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma. , 2007, Cancer genetics and cytogenetics.

[51]  A. Tobías.  Assessing the influence of a single study in the meta-anyalysis estimate , 1999 .